Researchers Develop Test for Super-Virulent C. diff Strains

Researchers at Rhode Island Hospital (Providence) have developed a new test for Clostridium difficile able to distinguish between strains of varying virulence, according to research published in the Journal of Molecular Diagnostics.

Advertisement

The test is based on rapid identification of genetic material unique to different strains of C. diff, which menaces hospitals, causing diarrhea, complications and even death. The researchers hope the test will help healthcare facilities screen patients for strains of C. diff that cause illness.

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

The incidence of C. diff has been on the rise in recent years, and the emergence of an especially severe strain of the bacteria has increased the need for better detection and prevention technology and practices, according to a Heart Transplant Death Risk Varies 900%.

More Articles on Quality:

Patient Navigators Facillitate Successful Chronic Care, Study Finds

Heart Trasplant Death Risk Varies 900%

Reducing Readmissions to Reduce Penalties: Where to Begin?

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.